Katie Herman

Conference Coverage

HER2-Low Breast Cancer in the National Cancer Database

12/09/2022

Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.

Daniel Peiffer, MD, PhD, and...

12/09/2022

Journal of Clinical Pathways

Conference Coverage

Low-Value Care Directly Leads to Development of Cancer Genomic Pathways

10/16/2022

Katie Herman ;

Craig Ostroff ;

Tatjana Kolevska, MD, explains at the 2022 Oncology Clinical Pathways Conference that digital pathways are the way of the future in regard to cancer care.

Tatjana Kolevska, MD, explains...

10/16/2022

Journal of Clinical Pathways

Conference Coverage

Precision Medicine and AI in Oncology Patient Care

10/16/2022

Katie Herman ;

Craig Ostroff ;

Tushar Pandey, CEO, SimBioSys, Inc, in his 2022 Oncology Clinical Pathways Congress presented on the value artificial intelligence brings to oncology patient care, and the need to move to guided intelligence.

Tushar Pandey, CEO, SimBioSys,...

10/16/2022

Journal of Clinical Pathways

Conference Coverage

HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy

12/07/2022

Katie Herman ;

Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.

Della Varghese, PharmD, PhD, and...

12/07/2022

Journal of Clinical Pathways